VRC
Home
Vaccine Research Center
Scientific Updates
SARS Vaccine Development
A Cooperative Research and Development Agreement and contract
have been established with GenVec, Inc. to produce pre-clinical
and clinical grade adenoviral vectors that express several
SARS proteins. The NIAID Vaccine Research Center plans to
evaluate the immunogenicity of these vectors preclinically,
and will continue to develop and test adenovector-based vaccine
candidates against SARS that are suitable for rapid advancement
toward clinical trials. In addition, the VRC has contracted
with Vical, Inc. to manufacture a SARS DNA based vaccine encoding
the spike (S) glycoprotein of the SARS coronavirus. Recent
studies have demonstrated that this vaccine induces T cell
and neutralizing antibody responses, as well as protective
immunity, in a mouse model. A Phase I trial of this recombinant
DNA vaccine developed at the VRC is being planned for late
2004 or early 2005.
|